Drug intelligence / Profile preview

E0671

Development stage: Unknown

Overview

E0671 is an investigational pharmaceutical drug that has been studied in a double-blind, comparative clinical trial for its efficacy and safety in combination with rabeprazole sodium for the treatment of gastric ulcers. The trial investigated a dosage of 150 mg/day of E0671 alongside 10 mg/day of rabeprazole sodium. No specific mechanism of action or developer for this drug is publicly available from the provided context.

Beyond the preview

Go deeper on E0671.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on E0671.

Explore the full profile